Stifel analyst Jonathan Block raised the firm’s price target on Idexx Laboratories (IDXX) to $510 from $460 and keeps a Hold rating on the shares after revisiting Q1 earnings reports across the analyst’s Animal Health, Dental and Sleep Apnea coverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDEXX Laboratories Updates Corporate Governance Structure
- Idexx Laboratories: Resilience and Growth Potential Amidst Challenging Conditions
- IDEXX Laboratories Reports Strong Q1 2025 Results
- IDEXX Laboratories’ Earnings Call: Strong Growth Amid Challenges
- Idexx Laboratories: Promising Developments Balanced by Market Challenges Leading to Hold Rating